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ABSTRACT
Background. The neutrophil/lymphocyte ratio (NLR) has
been reportedly associated with prognosis in cancer
patients by influencing both cancer progression and
chemosensitivity. However, the correlation between NLR
and the outcome of neoadjuvant chemotherapy (NAC) in
breast cancer patients remains unclear.
Methods. NLR was evaluated in 177 patients with breast
cancer treated with NAC with 5-fluorouracil, epirubicin,
and cyclophosphamide, followed by weekly paclitaxel and
subsequent curative surgery. The correlation between NLR
and prognosis, including the efficacy of NAC, was evalu-
ated retrospectively.
Results. NLR ranged from 0.5 to 10.6. Fifty-eight patients
with low NLR (\3.0) had a higher pathological complete
response (pCR) rate (p\ 0.001) and were more frequently
diagnosed with ER-negative/progesterone receptor (PR)-
negative/HER2-negative (triple-negative) breast cancer
(TNBC; p\ 0.001) compared with patients with high NLR
(C3.0). Among TNBC patients who achieved pCR, dis-
ease-free survival (p = 0.006) and overall survival
(p\ 0.001) were significantly longer in patients with low
NLR than in those with high NLR. Low NLR was
associated with a significantly favorable prognosis in
TNBC patients who achieved pCR, according to univariate
analysis (p = 0.044, hazard ratio = 0.06).
Conclusions. Low NLR may indicate high efficacy and
favorable outcome after NAC in patients with TNBC.
Treatment with neoadjuvant chemotherapy (NAC)
increases the rate of breast-conserving surgery and reduces
the risk of postoperative recurrence in patients with
resectable breast cancer.1–4 Efficacy is enhanced by the
combined use of anthracyclines and taxanes,1,5,6 and fur-
ther improvements in therapeutic effects may be expected
with the advent of molecular-targeting drugs.7,8 In addi-
tion, evaluation of the therapeutic effects of NAC can
provide valuable information.
Breast cancer can be classified into the following phe-
notypes: estrogen receptor (ER)-positive (luminal, normal
breast-like); human epidermal growth factor receptor
(HER) 2-overexpressing; and basal-like, based on cDNA
microarray analysis.9–11 The basal-like subtype displays
characteristics of myoepithelial cells/basal cells, and often
corresponds to so-called ER-negative/progesterone recep-
tor (PR)-negative/HER2-negative (triple-negative) breast
cancer (TNBC). Patients with TNBC do not benefit from
endocrine or anti-HER2 therapy, and chemotherapy is the
only treatment option.12–16 However, the efficacy of
chemotherapy varies among patients with TNBC, and
accurate methods for predicting the outcome not only help
to identify the direct treatment effects, but also help to
reduce adverse events caused by inappropriate treatment.
Abnormalities in white blood cell subpopulations, such
as neutrophilia and lymphopenia, have been reported in
tumor-bearing patients, and the neutrophil/lymphocyte
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ratio (NLR) has been found to be associated with prognosis
in patients following radical surgery.17–21 Neutrophils are
known to promote tumor cell proliferation, angiogenesis,
and distant metastasis, while lymphocytes play a central
role in the immune reaction against tumors. NLR may thus
be related to both prognosis and chemosensitivity.22,23
This single-center, retrospective study aimed to evaluate
NLR as a possible markers for predicting the outcome of
NAC in patients with TNBC in a consecutive patient series
treated with a standardized single protocol.
METHODS
Patient Background
A total of 177 patients with resectable, early-stage breast
cancer diagnosed as stage IIA (T1, N1, M0 or T2, N0, M0),
IIB (T2, N1, M0 or T3, N0, M0), or IIIA (T1-2, N2, M0 or
T3, N1-2, M0) were treated with NAC between 2007 and
2013. Tumor stage and T and N factors were stratified
based on the TNM Classification of Malignant Tumors,
UICC Sixth Edition.24 Breast cancer was confirmed his-
tologically by core needle biopsy and staged by systemic
imaging studies using computed tomography (CT), ultra-
sonography (US), and bone scintigraphy. Breast cancer was
classified into subtypes according to the immunohisto-
chemical expression of ER, PR, HER2, and Ki67. The
cutoffs for ER positivity and PR positivity were both[0 %
positive tumor cells with nuclear staining. Tumors with 3?
HER2 on immunohistochemical staining were considered
to show HER2 overexpression; tumors with 2? HER2
were further analyzed by fluorescence in situ hybridization;
and those with HER2/CER17 C 2.0 were also considered
to exhibit HER2 overexpression. A Ki67-labeling
index C 14 % tumor cells with nuclear staining was
determined to be positive.
All patients received a standardized protocol of NAC
consisting of four courses of FEC100 (500 mg/m2
fluorouracil, 100 mg/m2 epirubicin, and 500 mg/m2
cyclophosphamide) every 3 weeks, followed by 12 courses
of 80 mg/m2 paclitaxel administered weekly.25,26 Forty-
five patients had HER2-positive breast cancer and were
additionally administered weekly (2 mg/kg) or tri-weekly
(6 mg/kg) trastuzumab during paclitaxel treatment.27 All
patients underwent chemotherapy as outpatients. Thera-
peutic anti-tumor effects were assessed according to the
Response Evaluation Criteria in Solid Tumors (RECIST)
criteria.28 Pathological complete response (pCR) was
defined as the complete disappearance of the invasive
compartment of the lesion with or without intraductal
components, including in the lymph nodes. Patients
underwent mastectomy or breast-conserving surgery after
NAC. All patients who underwent breast-conserving sur-
gery were administered postoperative radiotherapy to the
remnant breast. Overall survival (OS) time was the period
from the initiation of NAC to the time of death from any
cause. Disease-free survival (DFS) was defined as freedom
from all local, loco-regional, and distant recurrences. All
patients were followed up by physical examination every
3 months, US every 6 months, and CT and bone scintig-
raphy annually. The median follow-up period for the
assessment of OS was 3.4 years (range, 0.6–6.0 years) and
for DFS was 3.1 years (range, 0.1–6.0 years). The study
protocol was approved by the Ethics Committee of Osaka
City University (#926). Written informed consent was
obtained from all subjects.
Blood Sample Analysis
Peripheral blood was obtained at the time of diagnosis,
before NAC. The numbers of white blood cells were
determined using a hemocytometer. The percentages of
different types of cells were determined using a Coulter LH
750 Hematology Analyzer (Beckman Coulter, Brea, CA,
USA). NLR was calculated from the preoperative blood
sample by dividing the absolute neutrophil count by the
absolute lymphocyte count. On the basis of previous
studies, an NLR value of 3.0 was used as the cutoff value to
discriminate between high-NLR (C3.0) and low-NLR
(\3.0).18,29–31
Statistical Analysis
Statistical analysis was performed using the SPSS ver-
sion 19.0 statistical software package (IBM, Armonk, NY,
USA). We examined the associations between NLR and
clinicopathologic variables using v2 tests. Multivariate
analysis of pCR was carried out using a binary logistic
regression model. The Kaplan–Meier method was used to
estimate DFS and OS, and the results between groups were
compared using log-rank tests. Multivariate analysis of
prognostic factors was carried out using a Cox regression
model. A p value\0.05 was considered significant. Cutoff
values for different biomarkers included in this study were
chosen before statistical analysis.18,29–32
RESULTS
Clinicopathological Responses of Primary Breast
Cancers to NAC
Clinical responses (pCR? partial response) were
observed in 151 patients (85.4 %). NAC-related pCR was
observed in 67 patients (37.9 %). The pCR rates were
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45.9 % (28/61) and 33.6 % (39/116) in patients with
TNBC and with non-TNBC, respectively (Supplemental
Table 1).
Among all cases, patients with pCR tended to have more
favorable DFS (p = 0.254, log-rank) and OS (p = 0.221,
log-rank) compared with those with non-pCR, though the
differences were not significant (Supplemental Fig. 1A, B).
However, TNBC patients with pCR had significantly better
DFS (p = 0.043, log-rank) and OS (p = 0.049, log-rank)
than those with non-pCR (Supplemental Fig. 1C, D). There
was no significant difference in DFS (p = 0.964, log-rank)
or OS (p = 0.975, log-rank) in relation to pCR among
patients with non-TNBC (Supplemental Fig. 1E, F).
Associations Between Clinicopathological Parameters
and NLR
NLR was determined in every sample and ranged from
0.5 to 10.6 (mean, 2.3; median, 2.0; standard deviation
0.5). Fifty-eight patients were judged as having low NLR
(32.8 %) and 119 as high NLR (67.2 %). Low NLR was
significantly correlated with younger age (p = 0.038),
premenopausal status (p = 0.037), pCR result (p\ 0.001),
and TNBC phenotype (p\ 0.001) (Table 1). Clinico-
pathological features were further investigated in TNBC
patients. TNBC patients with low NLRs had high Ki67
indexes (p = 0.002) and were significantly more likely to
achieve pCR (p\ 0.001). There was no significant corre-
lation between NLR and any other tested
clinicopathological parameters among TNBC patients
(Table 2).
Correlation Between NLR and Prognosis After NAC
There was no significant difference in DFS or OS among
all 177 patients (Figs. 1a, 2a) or among the 61 TNBC
patients (Figs. 1b, 2b) stratified by NLR. However, among
TNBC patients who achieved pCR, DFS (p = 0.006, log-
rank) and OS (p\ 0.001, log-rank) were both significantly
longer in patients with low NLR compared with patients
with high NLR (Figs. 1c, 2c). There was no significant
difference in DFS or OS in patients with non-pCR in
relation to NLR (Supplemental Fig. 2A–F). On univariate
TABLE 1 Correlation between clinicopathological features and
neutrophil to lymphocyte ratio in 177 all breast cancers
Parameters NLR (n = 177) (p value)
High (n = 119) Low (n = 58)
Age at operation 0.038
B56 52 (43.7 %) 35 (60.3 %)
[56 67 (56.3 %) 23 (39.7 %)
Menopause 0.037
Negative 42 (35.3 %) 30 (51.7 %)
Positive 77 (64.7 %) 28 (48.3 %)
Tumor size 0.053
B2 cm 20 (16.8 %) 4 (6.9 %)
[2 cm 99 (83.2 %) 54 (93.1 %)
Lymph node status 0.552
Negative 26 (21.8 %) 15 (25.9 %)
Positive 93 (78.2 %) 43 (74.1 %)
Nuclear grade 0.469
1, 2 94 (79.0 %) 43 (74.1 %)
3 25 (21.0 %) 15 (25.9 %)
Ki67 0.292
B14 % 53 (44.5 %) 21 (36.2 %)
[14 % 66 (55.5 %) 37 (63.8 %)
Intrinsic subtype \0.001
TNBC 25 (21.0 %) 36 (62.1 %)
non-TNBC 94 (79.0 %) 22 (37.9 %)
Pathological \0.001
pCR 34 (28.6 %) 33 (56.9 %)
non-pCR 85 (71.4 %) 25 (43.1 %)
NLR neutrophil-to-lymphocyte ratio, TNBC triple-negative breast
cancers, pCR pathological complete response
TABLE 2 Correlations between neutrophil to lymphocyte ratio and
clinicopathological parameters in 61 triple-negative breast cancers
Parameters TNBC (n = 61) (p value)
High (n = 25) Low (n = 36)
Age at operation 0.069
B56 8 (32.0 %) 20 (55.6 %)
[56 17 (68.0 %) 16 (44.4 %)
Menopause 0.274
Negative 7 (28.0 %) 15 (41.7 %)
Positive 18 (72.0 %) 21 (58.3 %)
Tumor size 0.610
B2 cm 3 (12.0 %) 4 (11.1 %)
[2 cm 22 (88.0 %) 32 (88.9 %)
Lymph node status 0.084
Negative 2 (8.0 %) 9 (25.0 %)
Positive 23 (92.0 %) 27 (75.0 %)
Nuclear grade 0.198
1, 2 20 (80.0 %) 24 (66.7 %)
3 5 (20.0 %) 12 (33.3 %)
Ki67 0.002
B14 % 13 (52.0 %) 5 (13.9 %)
[14 % 12 (48.0 %) 31 (86.1 %)
Pathological response \0.001
pCR 2 (8.0 %) 26 (72.2 %)
non-pCR 23 (92.0 %) 10 (27.8 %)
NLR neutrophil-to-lymphocyte ratio, TNBC triple-negative breast
cancers, pCR pathological complete response
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analysis for recurrence, low NLR showed more favorable
prognosis than high NLR (p = 0.044, hazard ratio
(HR) = 0.06) (Table 3). However, multivariate analysis
also demonstrated that low NLR status was not an inde-
pendent factor to indicate significantly more favorable
prognosis of the patients compared with high-NLR status
(p = 0.173, HR = 0.09).
DISCUSSION
NLR scores in breast cancer patients have been
reported previously.18,19 However, the current study
specifically enrolled patients who were eligible for NAC.
Our results confirmed the correlation between high NLR
and older age or post-menopausal status, as reported
previously,18,19 suggesting that NLR may be influenced
by the patient’s systemic condition. We also found that
patients with non-TNBC subtype had significantly higher
NLRs. In the present study, the proportion of patients
with non-TNBC was smaller (116/177, 65 %) than in
previous reports.18,19 In addition, the characteristics of the
patients with non-TNBC were biased because of the
exclusion of patients unsuitable for NAC, such as older
patients and those with early-stage or disseminated dis-
ease. The current study population was therefore not
suitable for investigating the correlation between NLR
and tumor subtype.
Azab et al. studied 465 patients and demonstrated sig-
nificantly poorer survival in those with high (highest
quartile) NLR.19 Dircan et al. reported similar findings.33
Several other studies have also shown a correlation
between high NLR and prognosis in breast cancer patients
with selected features, such as luminal A phenotype.18
NLR is known to be particularly influenced in patients with
advanced-stage disease,17,18 though patients with stage I or
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FIG. 2 There was no significant difference in overall survival (OS)
in relation to NLR among all 177 breast cancer patients (a), or among
61 TNBC patients (b). However, among TNBC patients who achieved
pCR, OS (p\ 0.001) was significantly longer in patients with low
NLR after NAC compared with patients with high NLR (c)
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FIG. 1 There was no significant difference in disease-free survival
(DFS) in relation to NLR among all 177 breast cancer patients (a), or
among 61 TNBC patients (b). However, among TNBC patients who
achieved pCR, DFS (p = 0.006) was significantly longer in patients
with low NLR after NAC, compared with patients with high NLR (c)
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strict inclusion criteria may explain the apparent lack of a
clear correlation between NLR and prognosis.
The main factor influencing prognosis in our series was
the efficacy of NAC, which was significantly correlated
with NLR. Patients with a low NLR had a significantly
higher pCR rate compared with patients with a high NLR.
Moreover, the relationship between NLR and the efficacy
of NAC differed between subtypes; NLR was significantly
associated with NLR in patients with TNBC, but not in
those with non-TNBC. The meaning of pCR is known to
differ according to breast cancer subtype, and significant
survival benefit only occurs in TNBC patients who achieve
pCR.34 Effective biomarkers for predicting the efficacy of
NAC in TNBC patient are therefore needed. In the present
study, low NLR showed a close correlation with a favor-
able prognosis in patients with TNBC who achieved pCR.
This observation may indicate the value of measuring NLR
in TNBC patients who require NAC in order to predict the
efficacy of the treatment.
In TNBC, the proliferation marker Ki67 has been sug-
gested as the pCR predictive biomarker of NAC.35 And the
TNBC patients in the present study showed a correlation
between low NLR and the high Ki67 index group. There-
fore, we thought that patients with a low NLR achieved a
high pCR rate. However, in the factor analysis, only low
NLR was useful as a favorable prognosis factor in NAC.
Breast cancer is not generally regarded as an immune-
related disorder. However, tumor-infiltrating lymphocytes
and the expression of immune markers such as PD1, PDL1,
and CTLA4 have recently been found to correlate with
pCR in TNBC.36–41 NLR is relatively low in tumor sub-
types with high lymphocyte activity, such as TNBC.42–44
Chemotherapy further activates the immune response in
patients with low NLR, thereby accelerating the anti-tumor
effect.17–19,21,45
Recent studies have suggested that TNBC can be clas-
sified into seven subtypes, depending on the gene
expression profile,44,46 and sensitivities to treatment are
thought to differ among the different subtypes.34 BL-1 is a
basal-like subtypes that demonstrates a high cell mass in
culture along with high expression levels of cell cycle and
DNA-injury-responsive genes, and which shows high
chemosensitivity. In contrast, the BL-2 basal-like subtype
and luminal androgen receptor subtype, which overex-
presses androgen receptors, both have low pCR rates.34 The
immunomodulatory subtype overexpresses genes related to
immune reactions and has demonstrated higher sensitivity
to chemotherapy and a more favorable prognosis compared
with other subtypes.47 The results of the present study
suggest that NLR may be correlated with TNBC subtypes
and different outcomes after successful NAC.
In the present study, NLR was closely correlated with
prognosis in TNBC patients after successful NAC, sug-
gesting that low NLR may represent a useful surrogate
marker in patients with TNBC. NLR can be measured
easily without the need for any special equipment or
invasive procedures. Further prospective studies are
therefore warranted to confirm these preliminary results
and to investigate the correlations between TNBC charac-
teristics or subtypes and NLR.
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